WO2013020017A1 - Trans-clomiphene metabolites and uses thereof - Google Patents
Trans-clomiphene metabolites and uses thereof Download PDFInfo
- Publication number
- WO2013020017A1 WO2013020017A1 PCT/US2012/049451 US2012049451W WO2013020017A1 WO 2013020017 A1 WO2013020017 A1 WO 2013020017A1 US 2012049451 W US2012049451 W US 2012049451W WO 2013020017 A1 WO2013020017 A1 WO 2013020017A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clomiphene
- trans
- composition
- female
- administering
- Prior art date
Links
- LTZHRTXXQIPLOH-OCEACIFDSA-N CCN(CC)CCOc(cc1)ccc1/C(/c(cc1)ccc1O)=C(\c1ccccc1)/Cl Chemical compound CCN(CC)CCOc(cc1)ccc1/C(/c(cc1)ccc1O)=C(\c1ccccc1)/Cl LTZHRTXXQIPLOH-OCEACIFDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201402168A UA113291C2 (en) | 2011-08-04 | 2012-03-08 | TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS |
KR1020147004588A KR20140054110A (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
CN201280038230.6A CN103702975B (en) | 2011-08-04 | 2012-08-03 | ENCLO metabolite and uses thereof |
EP18161551.9A EP3351527A1 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
EP12750508.9A EP2744777A1 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
AU2012289964A AU2012289964B2 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
MX2014000825A MX355316B (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof. |
BR112014000908A BR112014000908A2 (en) | 2011-08-04 | 2012-08-03 | compound, pharmaceutical composition and its uses and methods for treating secondary hypogonadism or associated disorder, infertility in women, type 2 diabetes in male humans, breast cancer in women and endometrial, ovarian or uterine cancer in women, to prevent the transition from metabolic syndrome to type 2 diabetes in male human and breast cancer in female and to reduce fasting blood glucose levels in male human |
NZ621892A NZ621892B2 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
CA2841572A CA2841572C (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
EA201490416A EA201490416A1 (en) | 2011-08-04 | 2012-08-03 | TRANS-CLOMIFENE METABOLITES AND THEIR APPLICATION |
JP2014524097A JP6433785B2 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
US14/236,868 US9981906B2 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
IL230287A IL230287B (en) | 2011-08-04 | 2014-01-02 | Trans-clomiphene metabolites and uses thereof |
ZA2014/00406A ZA201400406B (en) | 2011-08-04 | 2014-01-17 | Trans-clomiphene metabolites and uses thereof |
HK14109682.8A HK1196349A1 (en) | 2011-08-04 | 2014-09-26 | Trans clomiphene metabolites and uses thereof |
AU2017204171A AU2017204171A1 (en) | 2011-08-04 | 2017-06-20 | Trans-Clomiphene Metabolites And Uses Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161515278P | 2011-08-04 | 2011-08-04 | |
US61/515,278 | 2011-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013020017A1 true WO2013020017A1 (en) | 2013-02-07 |
Family
ID=46724628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/049451 WO2013020017A1 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
Country Status (21)
Country | Link |
---|---|
US (1) | US9981906B2 (en) |
EP (2) | EP3351527A1 (en) |
JP (2) | JP6433785B2 (en) |
KR (1) | KR20140054110A (en) |
CN (1) | CN103702975B (en) |
AU (2) | AU2012289964B2 (en) |
BR (1) | BR112014000908A2 (en) |
CA (1) | CA2841572C (en) |
CL (1) | CL2014000268A1 (en) |
CO (1) | CO6862154A2 (en) |
CR (1) | CR20140124A (en) |
EA (1) | EA201490416A1 (en) |
HK (1) | HK1196349A1 (en) |
IL (1) | IL230287B (en) |
MX (1) | MX355316B (en) |
MY (2) | MY191802A (en) |
NI (1) | NI201400008A (en) |
SG (1) | SG10201606425WA (en) |
UA (1) | UA113291C2 (en) |
WO (1) | WO2013020017A1 (en) |
ZA (1) | ZA201400406B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014070523A1 (en) * | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
WO2017182097A1 (en) | 2016-04-22 | 2017-10-26 | F.I.S. - Fabbrica Italiana Sintetici S.P.A. | Process for the preparation of enclomiphene citrate having needle shaped crystal habit. |
US9981906B2 (en) | 2011-08-04 | 2018-05-29 | Repros Therapeutics Inc. | Trans-clomiphene metabolites and uses thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120284764A1 (en) * | 2011-05-05 | 2012-11-08 | Keith Ball | Method and system for requesting services by a media device |
NZ702467A (en) | 2012-05-31 | 2016-07-29 | Repros Therapeutics Inc | Formulations and methods for vaginal delivery of antiprogestins |
CA2888377C (en) | 2012-11-02 | 2021-02-02 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
WO2017123577A1 (en) * | 2016-01-12 | 2017-07-20 | Repros Therapeutics Inc. | Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions |
WO2017147264A1 (en) * | 2016-02-25 | 2017-08-31 | Aspen Park Pharmaceuticals, Inc. | Oral dosage form of both clomiphene isomers and method of using same to treat secondary hypogonadism |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04312522A (en) | 1991-04-08 | 1992-11-04 | Yoshiaki Kawashima | Production of sustained release tablet |
WO1995035093A1 (en) | 1994-06-17 | 1995-12-28 | University Of Nebraska Board Of Regents | In situ gel-forming delivery vehicle for bio-affecting substances, and method of use |
US6096338A (en) | 1994-03-16 | 2000-08-01 | R. P. Scherer Corporation | Delivery systems for hydrophobic drugs |
US6126969A (en) | 1996-02-27 | 2000-10-03 | L. Perrigo Company | Immediate release/sustained release compressed tablets |
US6129933A (en) | 1991-12-24 | 2000-10-10 | Purdue Pharma Lp | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US6143353A (en) | 1992-01-27 | 2000-11-07 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US6190591B1 (en) | 1996-10-28 | 2001-02-20 | General Mills, Inc. | Embedding and encapsulation of controlled release particles |
US6221399B1 (en) | 1995-08-17 | 2001-04-24 | Csir | Method of making controlled release particles of complexed polymers |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7368480B2 (en) | 2001-07-09 | 2008-05-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
US20080242726A1 (en) | 2004-07-14 | 2008-10-02 | Podolski Joseph S | Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol |
US20090099265A1 (en) | 2007-10-16 | 2009-04-16 | Repros Therapeutics Inc. | Trans-clomiphene for metabolic syndrome |
US20090215906A1 (en) | 2005-02-04 | 2009-08-27 | Repros Therapeutics Inc. | Methods and materials with trans-clomiphene for the treatment of male infertility |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2914563A (en) | 1957-08-06 | 1959-11-24 | Wm S Merrell Co | Therapeutic composition |
IT951631B (en) | 1971-03-18 | 1973-07-10 | Richardson Merrell Spa | USEFUL COMPOUNDS FOR THE SEPARATION OF GEOMETRIC AND STRUCTURAL OPTICAL ISOMERS AND RELATED SYNTHESIS PROCEDURE |
US4061733A (en) | 1976-10-15 | 1977-12-06 | Narayan Vishwanath Gunjikar | Veterinary compositions for inducing estrus in animals and method |
US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
DE3660489D1 (en) | 1985-06-08 | 1988-09-15 | Asta Pharma Ag | Derivatives of 1,1,2,2-tetramethyl-1,2-bis(2-fluoro-4-hydroxyphenyl) ethane |
US4820736A (en) * | 1987-03-20 | 1989-04-11 | Yale University | Use of clomiphene to predict fertility in a human female |
GB8926171D0 (en) | 1989-11-20 | 1990-01-10 | Applied Research Systems | Treatment of infertility |
AU672234B2 (en) * | 1992-09-15 | 1996-09-26 | Merrell Dow Pharmaceuticals Inc. | Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors |
US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
DE4435368A1 (en) | 1994-09-22 | 1996-03-28 | Schering Ag | Use of aromatase inhibitors for the manufacture of a medicament for the treatment of a relative androgen deficiency in men |
IL120262A (en) | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
WO1998044021A1 (en) | 1997-04-03 | 1998-10-08 | Guilford Pharmaceuticals Inc. | Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same |
US6653297B1 (en) | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
US6342250B1 (en) | 1997-09-25 | 2002-01-29 | Gel-Del Technologies, Inc. | Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices |
US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US20040176470A1 (en) | 1998-05-07 | 2004-09-09 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
JP4443048B2 (en) | 1998-07-30 | 2010-03-31 | ストラー・エンタープライジズ・インコーポレーテツド | Treatment of plants with salicylic acid and organic amines. |
EP1102753B1 (en) | 1998-08-07 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Pyrazoles as estrogen receptor modulators |
JP5184727B2 (en) | 1999-06-11 | 2013-04-17 | ワトソン ファーマシューティカルズ, インコーポレイテッド | Parenteral androgenic steroid administration to women |
CA2321321A1 (en) | 1999-09-30 | 2001-03-30 | Isotis B.V. | Polymers loaded with bioactive agents |
US6258802B1 (en) | 1999-10-06 | 2001-07-10 | Medical College Of Hampton Roads | Corticoid therapy |
AU3104301A (en) | 2000-01-20 | 2001-07-31 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
KR20020073566A (en) | 2000-01-28 | 2002-09-27 | 앙도르쉐르슈 인코포레이티드 | Selective estrogen receptor modulators in combination with estrogens |
US7067557B2 (en) | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
JP2003534375A (en) | 2000-05-26 | 2003-11-18 | フィッチ,ハリー | Treatment of androgen deficiency in men with selective antiestrogens |
ATE278421T1 (en) | 2000-08-11 | 2004-10-15 | Wyeth Corp | METHOD FOR TREATING ESTROGEN RECEPTOR POSITIVE CARCINOMA |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20040192598A1 (en) | 2000-10-11 | 2004-09-30 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
WO2002055020A2 (en) | 2000-12-11 | 2002-07-18 | Testocreme Llc | Topical testosterone formulations and associated methods |
US7173064B2 (en) | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
AU2002330031B2 (en) | 2001-09-21 | 2007-07-05 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
US20060269611A1 (en) | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US7105679B2 (en) | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US20050042268A1 (en) | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20060293294A1 (en) | 2004-09-03 | 2006-12-28 | Hormos Medical Corporation | Method for treatment or prevention of androgen deficiency |
CN101115709B (en) * | 2004-12-13 | 2011-04-13 | 小野药品工业株式会社 | Aminocarboxylic acid derivative and medicinal use thereof |
WO2006086544A2 (en) | 2005-02-11 | 2006-08-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
JP5785680B2 (en) | 2005-03-22 | 2015-09-30 | リプロス セラピューティクス インコーポレイテッド | Dosing regimen for trans-clomiphene |
WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
CA2617905A1 (en) * | 2005-08-05 | 2007-02-15 | Repros Therapeutics Inc. | Methods and compositions for treating female infertility using clomiphene |
US7613937B2 (en) | 2005-10-31 | 2009-11-03 | Hewlett-Packard Development Company, L.P. | Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer |
CA2642761A1 (en) | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
EP1829534A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome |
WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
EP2276198B1 (en) | 2007-06-26 | 2012-01-18 | Media Patents, S. L. | Device for managing multicast groups |
WO2009020521A2 (en) | 2007-08-03 | 2009-02-12 | The Brigham And Women's Hospital, Inc. | Identification and treatment of estrogen responsive prostate tumors |
US20100111901A1 (en) | 2008-11-03 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Triazole inhibitors of aromatase |
TW201500041A (en) | 2008-11-07 | 2015-01-01 | Repros Therapeutics Inc | Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2 |
US20100144687A1 (en) | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
UA113291C2 (en) | 2011-08-04 | 2017-01-10 | TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS | |
CA2881604C (en) | 2011-08-09 | 2021-09-14 | Kenneth W. Adams | Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males |
ES2681023T3 (en) | 2012-02-29 | 2018-09-11 | Repros Therapeutics Inc. | Combination therapy to treat androgen deficit |
EA201590421A1 (en) | 2012-08-21 | 2015-06-30 | Репрос Терапьютикс Инк. | COMPOSITIONS OF TRANS-CLOMIPHENE AND THEIR APPLICATION |
CN103351304B (en) | 2013-07-01 | 2015-12-09 | 暨明医药科技(苏州)有限公司 | A kind of synthetic method of MRL-41 |
-
2012
- 2012-03-08 UA UAA201402168A patent/UA113291C2/en unknown
- 2012-08-03 BR BR112014000908A patent/BR112014000908A2/en active Search and Examination
- 2012-08-03 MY MYPI2017001676A patent/MY191802A/en unknown
- 2012-08-03 US US14/236,868 patent/US9981906B2/en not_active Expired - Fee Related
- 2012-08-03 EP EP18161551.9A patent/EP3351527A1/en not_active Withdrawn
- 2012-08-03 KR KR1020147004588A patent/KR20140054110A/en not_active IP Right Cessation
- 2012-08-03 EA EA201490416A patent/EA201490416A1/en unknown
- 2012-08-03 WO PCT/US2012/049451 patent/WO2013020017A1/en active Application Filing
- 2012-08-03 SG SG10201606425WA patent/SG10201606425WA/en unknown
- 2012-08-03 AU AU2012289964A patent/AU2012289964B2/en not_active Ceased
- 2012-08-03 MX MX2014000825A patent/MX355316B/en active IP Right Grant
- 2012-08-03 CN CN201280038230.6A patent/CN103702975B/en not_active Expired - Fee Related
- 2012-08-03 EP EP12750508.9A patent/EP2744777A1/en not_active Withdrawn
- 2012-08-03 CA CA2841572A patent/CA2841572C/en not_active Expired - Fee Related
- 2012-08-03 MY MYPI2014000022A patent/MY170718A/en unknown
- 2012-08-03 JP JP2014524097A patent/JP6433785B2/en not_active Expired - Fee Related
-
2014
- 2014-01-02 IL IL230287A patent/IL230287B/en active IP Right Grant
- 2014-01-17 ZA ZA2014/00406A patent/ZA201400406B/en unknown
- 2014-01-24 CO CO14014339A patent/CO6862154A2/en unknown
- 2014-01-30 NI NI201400008A patent/NI201400008A/en unknown
- 2014-02-03 CL CL2014000268A patent/CL2014000268A1/en unknown
- 2014-03-13 CR CR20140124A patent/CR20140124A/en unknown
- 2014-09-26 HK HK14109682.8A patent/HK1196349A1/en not_active IP Right Cessation
-
2017
- 2017-06-20 AU AU2017204171A patent/AU2017204171A1/en not_active Abandoned
-
2018
- 2018-10-01 JP JP2018186696A patent/JP2019023210A/en active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04312522A (en) | 1991-04-08 | 1992-11-04 | Yoshiaki Kawashima | Production of sustained release tablet |
US6129933A (en) | 1991-12-24 | 2000-10-10 | Purdue Pharma Lp | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US6143353A (en) | 1992-01-27 | 2000-11-07 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US6096338A (en) | 1994-03-16 | 2000-08-01 | R. P. Scherer Corporation | Delivery systems for hydrophobic drugs |
WO1995035093A1 (en) | 1994-06-17 | 1995-12-28 | University Of Nebraska Board Of Regents | In situ gel-forming delivery vehicle for bio-affecting substances, and method of use |
US6221399B1 (en) | 1995-08-17 | 2001-04-24 | Csir | Method of making controlled release particles of complexed polymers |
US6126969A (en) | 1996-02-27 | 2000-10-03 | L. Perrigo Company | Immediate release/sustained release compressed tablets |
US6190591B1 (en) | 1996-10-28 | 2001-02-20 | General Mills, Inc. | Embedding and encapsulation of controlled release particles |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7368480B2 (en) | 2001-07-09 | 2008-05-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
US7759360B2 (en) | 2001-07-09 | 2010-07-20 | Repros Therapeutics Inc. | Methods and materials for the treatment of testosterone deficiency in men |
US20080242726A1 (en) | 2004-07-14 | 2008-10-02 | Podolski Joseph S | Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol |
US20090215906A1 (en) | 2005-02-04 | 2009-08-27 | Repros Therapeutics Inc. | Methods and materials with trans-clomiphene for the treatment of male infertility |
US20090099265A1 (en) | 2007-10-16 | 2009-04-16 | Repros Therapeutics Inc. | Trans-clomiphene for metabolic syndrome |
Non-Patent Citations (10)
Title |
---|
BOIAN GANCHEV ET AL: "Quantification of clomiphene metabolite isomers in human plasma by rapid-resolution liquid chromatographyâ electrospray ionizationâ tandem mass spectrometry", ANALYTICAL AND BIOANALYTICAL CHEMISTRY, SPRINGER, BERLIN, DE, vol. 400, no. 10, 1 May 2011 (2011-05-01), pages 3429 - 3441, XP019924908, ISSN: 1618-2650, DOI: 10.1007/S00216-011-5045-9 * |
DANGPRASIT ET AL., DRUG. DEVEL. AND INCL. PHARM., vol. 21, no. 20, 1995, pages 2323 - 2337 |
ERNST ET AL., J. PHARMACEUT. SCI., vol. 65, 1976, pages 148 |
KHARENKO, INTERN. SYMP. CONTROL REL. BIOACT. MATER., vol. 22, 1995, pages 232 - 233 |
MESHALI ET AL., INT. J. PHAR., vol. 89, 1993, pages L77 - L81 |
PETER C. RUENITZ ET AL: "Phenolic metabolites of clomiphene. [(E,Z)-2-[4-(1,2-diphenyl-2-chlorovinyl)phenoxy]ethyl]diethylamine. Preparation, electrophilicity, and effects in MCF 7 breast cancer cells", JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 1, 1 January 1989 (1989-01-01), pages 192 - 197, XP055039844, ISSN: 0022-2623, DOI: 10.1021/jm00121a035 * |
R.JEFFREY BAUMANN ET AL: "Clomiphene Analogs with Activity In Vitro and In Vivo against Human Breast Cancer Cells", BIOCHEMICAL PHARMACOLOGY, vol. 55, no. 6, 1 March 1998 (1998-03-01), pages 841 - 851, XP055039842, ISSN: 0006-2952, DOI: 10.1016/S0006-2952(97)00574-1 * |
See also references of EP2744777A1 |
TENOVER ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 64, 1987, pages 1118 |
TENOVER ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 64, pages 1103 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9981906B2 (en) | 2011-08-04 | 2018-05-29 | Repros Therapeutics Inc. | Trans-clomiphene metabolites and uses thereof |
WO2014070523A1 (en) * | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
US9687458B2 (en) | 2012-11-02 | 2017-06-27 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
WO2017182097A1 (en) | 2016-04-22 | 2017-10-26 | F.I.S. - Fabbrica Italiana Sintetici S.P.A. | Process for the preparation of enclomiphene citrate having needle shaped crystal habit. |
Also Published As
Publication number | Publication date |
---|---|
MY170718A (en) | 2019-08-27 |
ZA201400406B (en) | 2014-11-26 |
KR20140054110A (en) | 2014-05-08 |
CL2014000268A1 (en) | 2014-11-14 |
UA113291C2 (en) | 2017-01-10 |
IL230287A0 (en) | 2014-03-06 |
JP6433785B2 (en) | 2018-12-05 |
IL230287B (en) | 2019-07-31 |
AU2012289964A1 (en) | 2014-01-30 |
CN103702975B (en) | 2016-03-16 |
MY191802A (en) | 2022-07-15 |
US20140163114A1 (en) | 2014-06-12 |
EA201490416A1 (en) | 2014-11-28 |
MX355316B (en) | 2018-04-16 |
CO6862154A2 (en) | 2014-02-10 |
NZ621892A (en) | 2016-03-31 |
AU2012289964B2 (en) | 2017-03-23 |
CA2841572C (en) | 2020-10-13 |
EP2744777A1 (en) | 2014-06-25 |
BR112014000908A2 (en) | 2017-02-21 |
SG10201606425WA (en) | 2016-09-29 |
CR20140124A (en) | 2014-05-13 |
EP3351527A1 (en) | 2018-07-25 |
JP2019023210A (en) | 2019-02-14 |
CN103702975A (en) | 2014-04-02 |
HK1196349A1 (en) | 2014-12-12 |
CA2841572A1 (en) | 2013-02-07 |
US9981906B2 (en) | 2018-05-29 |
MX2014000825A (en) | 2014-02-27 |
JP2014529584A (en) | 2014-11-13 |
NI201400008A (en) | 2015-12-10 |
AU2017204171A1 (en) | 2017-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012289964B2 (en) | Trans-clomiphene metabolites and uses thereof | |
Y Maximov et al. | The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice | |
TWI359015B (en) | Pharmaceutical composition for treatment or preve | |
TW200410711A (en) | Prevention and treatment of androgen-deprivation induced osteoporosis | |
EP2826475A1 (en) | Trans-clomiphene for treating diabetes in hypogonadal men | |
JP2021046448A (en) | Trans-clomiphene for use in cancer therapy | |
JP2023525571A (en) | Concomitant treatment of liver damage | |
TWI458478B (en) | Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2 | |
CN1988909A (en) | Compositions comprising 5-alpha reductase inhibitors and serms and methods of use thereof | |
EP4149453A1 (en) | Combination treatment of liver disorders | |
PL193315B1 (en) | E-2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]ethanol and pharmacological compositions containing same | |
NZ621892B2 (en) | Trans-clomiphene metabolites and uses thereof | |
JP2021503448A (en) | Pharmaceutical combination containing LSZ102 and ribociclib | |
EP3300725A2 (en) | Selective estrogen receptor modulators with short half-lives and uses thereof | |
von Deutsch et al. | Anabolic doping agents | |
KR20180112048A (en) | Oral formulation of clomiphene isomers and methods of using them for the treatment of hypogonadism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201280038230.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12750508 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2841572 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/000825 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14014339 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2014524097 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2012289964 Country of ref document: AU Date of ref document: 20120803 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012750508 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14236868 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20147004588 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201402168 Country of ref document: UA Ref document number: 201490416 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2014-000124 Country of ref document: CR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014000908 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014000908 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140114 |